United States Copper Index Fund vs Illumina, Inc. — how do they compare? United States Copper Index Fund trades at $39.91 (market cap $716.81M), while Illumina, Inc. trades at $264.24 (market cap $40.43B). The key difference: Illumina, Inc. is far larger — about 56.4× United States Copper Index Fund's market cap, and United States Copper Index Fund is more actively traded (388,730 versus 2,948,626). Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Illumina, Inc. for 83 Days on average.
| CPER | ILMN | |
|---|---|---|
Market Cap | $716.81M | $40.43B |
Volume | 388,730 | 2,948,626 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $293.69 |
52-Week Low | $30.27 | $91.00 |
Typical Hold Time | 48 Days | 83 Days |
Enterprise Value | — | $41.79B |
Signals from Pluang's Aura AI — not financial advice
CPER trades at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish moving averages but neutral oscillators, with key support at $39. Recent news highlights strong copper demand driven by AI infrastructure, though some articles note price volatility. Financial ratios are unavailable in the provided data.
The outlook for CPER is mixed, balancing positive copper demand trends against near-term price pressure. Investment opportunity lies in exposure to the essential metal for AI and electrification, but risks include commodity price swings and operational challenges in the mining sector. Investors should weigh sector momentum against inherent volatility.
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →